Acquisition by Raul Rodriguez of 300000 shares of Rigel Pharmaceuticals at 1.87 subject to Rule 16b-3

ZHCLF Stock  USD 0.0001  0.00  0.00%   
Roughly 81 percent of all Zenith Capital's stockholders are aggressively thinking of buying. The analysis of overall sentiment of trading Zenith Capital Corp pink sheet suggests that a large number of investors are excited at this time. The current market sentiment, together with Zenith Capital's historical and current headlines, can help investors time the market. In addition, many technical investors use Zenith Capital Corp stock news signals to limit their universe of possible portfolio assets.
Zenith Capital pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Zenith daily returns and investor perception about the current price of Zenith Capital Corp as well as its diversification or hedging effects on your existing portfolios.
  
Filed transaction by Rigel Pharmaceuticals Director, Officer Ceo, President. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Acquisition of 300000 employee stock option (right to buy) at 1.87 of Rigel Pharmaceuticals by Raul Rodriguez on 22nd of November 2024. This event was filed by Rigel Pharmaceuticals with SEC on 2024-02-28. Statement of changes in beneficial ownership - SEC Form 4. Raul Rodriguez currently serves as ceo and president director and member of fin. committee of Rigel Pharmaceuticals

Zenith Capital Fundamental Analysis

We analyze Zenith Capital's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zenith Capital using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zenith Capital based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Valuation

Current Valuation Comparative Analysis

Zenith Capital is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Zenith Capital Corp Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zenith Capital pink sheet to make a market-neutral strategy. Peer analysis of Zenith Capital could also be used in its relative valuation, which is a method of valuing Zenith Capital by comparing valuation metrics with similar companies.

Peers

Zenith Capital Related Equities

BPMCBlueprint Medicines   6.80   
0%
35.0%
INBXInhibrx   5.16   
0%
26.0%
LXRXLexicon Pharmaceuticals   4.48   
0%
23.0%
MCRBSeres Therapeutics   4.11   
0%
21.0%
PRTGPortage Biotech   3.92   
0%
20.0%
AMLXAmylyx Pharmaceuticals   3.80   
0%
19.0%
ELVNEnliven Therapeutics   3.37   
0%
17.0%
ARVNArvinas   2.55   
0%
13.0%
FENCFennec Pharmaceuticals   2.18   
0%
11.0%
HOPHFHemogenyx Pharmaceuticals   0.00   
0%
0%
CMVLFCellectis   0.00   
0%
0%
CELCCelcuity LLC   0.74   
3.0%
0%
PLXProtalix Biotherapeutics   2.10   
10.0%
0%
PMNProMIS Neurosciences   4.05   
20.0%
0%
CVALFCovalon Technologies   5.15   
26.0%
0%
IOVAIovance Biotherapeutics   19.39   
100.0%
0%

Complementary Tools for Zenith Pink Sheet analysis

When running Zenith Capital's price analysis, check to measure Zenith Capital's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zenith Capital is operating at the current time. Most of Zenith Capital's value examination focuses on studying past and present price action to predict the probability of Zenith Capital's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zenith Capital's price. Additionally, you may evaluate how the addition of Zenith Capital to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Commodity Directory
Find actively traded commodities issued by global exchanges
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities